Targeted therapy combination for previously treated large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new targeted therapy (pirtobrutinib) combined with standard chemo-immunotherapy, with or without an extra targeted drug (polatuzumab vedotin), for people whose large B-cell lymphoma has returned or not responded after prior BTK inhibitor treatment. The goal is to see if this combination can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of large B-cell lymphoma (DLBCL) that has come back or not responded after treatment with a BTK inhibitor (a type of targeted therapy).
- Doctors confirmed your exact lymphoma subtype (like MCD, BN2, N1, double-expressor, or intravascular).
- You have at least one tumor that can be measured on a scan (over 1 cm or 1.5 cm).
- You are generally able to care for yourself (ECOG 0–2), and you are 18 years or older.
- Your major organs (like liver, kidneys, and heart) are working well enough, based on routine tests.
- You have not had lymphoma spread to the brain or spinal cord, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
This trial tests a combination of three targeted drugs (polatuzumab vedotin, zanubrutinib, and R-CHP) for people newly diagnosed with a specific subtype of DLBCL called non-GCB. The goal is to see if this powerful mix can work better than standard treatment.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a combination of three drugs—pirtobrutinib, lisaftoclax, and rituximab—for people with relapsed or refractory DLBCL who have already had at least one prior treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial tests a new drug combo for people with an aggressive type of large b-cell lymphoma. It aims to see if adding the new drug to standard chemo plus an antibody therapy is safe and works better.
This trial tests a combination of targeted therapy (Orelabrutinib) plus standard chemotherapy (Pola-R-CHP) for people with untreated non-GCB diffuse large B-cell lymphoma. The goal is to see if this new mix works better than the usual treatment.
Hear when a new Relapsed and Refractory DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.